Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia
3 - 75 Years, Male and Female
BMT CTN 2207 (primary)
NCI-2024-06876
BMT CTN Protocol 2207
Summary
BMT CTN 2207 will investigate the use of marrow transplantation for treatment of severe
aplastic anemia that has not previously been treated.
Objectives
This study is a prospective, multicenter Phase II study of hematopoietic stem cell
transplantation for previously untreated patients with severe aplastic anemia (SAA).
Severe Aplastic Anemia (SAA) is a rare condition in which the body stops producing enough
new blood cells. Patients with aplastic anemia have low white blood cells (cells which
fight infection), low red blood cells (cells that carry oxygen throughout the body), and
low platelets (cells that help form clots and prevent bleeding). Treatments for SAA seeks
to repair this abnormal immune system attack and allow the bone marrow to make the normal
amount of blood cells. This can be done with a bone marrow transplant or with medications
to suppress the immune system.
Historically, transplant therapy for SAA has been reserved for patients under 40 years
old who had an available fully matched related donor. The standard treatment for older
patients with SAA and patients who do not have a fully matched related donor has been
treatment using transfusions, medications that suppress the immune system
(immunosuppressive therapy, IST), and medications that try to stimulate the bone marrow
to produce more cells. For these patients, transplant was used only if a patient did not
respond to these interventions. However, progress has made transplantation safer and
allowed for half-matched related donor or full or partially-matched unrelated donors to
be used with success rates similar to fully matched related donors in many situations.
The goals of this study are to determine if patients with SAA who have not received
previous treatment for SAA can be treated effectively with transplant as their first SAA
therapy.
This is a parallel cohort study comprised of two cohorts based on donor selection:
haploidentical related donors and unrelated donors. The accrual goal is 30 participants
enrolled and starting protocol-specified conditioning in each cohort, yielding 60
participants in total. Participants will be treated with a reduced-intensity preparative
regimen of fludarabine (150 mg/m2), cyclophosphamide (29 mg/kg), low dose total body
irradiation (TBI, 400 cGy), and Thymoglobulin® (4.5 mg/kg). Bone marrow will be collected
from donors and fresh (not cryopreserved) cells will be given to patients. GVHD
prophylaxis will be with post-HSCT cyclophosphamide (100 mg/kg), tacrolimus, and
mycophenolate mofetil (MMF). All patients will receive the same conditioning regimen and
GVHD prophylaxis. Participants will be followed for 1 year post-transplant.
Eligibility
- Age 3 years to 75 years
- Confirmed diagnosis of acquired SAA defined as: a. Bone marrow cellularity < 25% or variable marrow cellularity but with < 30% residual hematopoietic cells deemed HYPOcellular for age AND b. Two (2) out of 3 of the following (in peripheral blood). i. Neutrophils < 0.5 x109/L ii. Platelets < 20 x109/L iii. Reticulocyte count < 20 x109/L (< 60 x 109/L using an automated analysis)
- No suitable fully matched related donor as per Investigator's discretion (6/6 match for HLA A and B at intermediate or high-resolution and DRB1 at high-resolution using deoxyribonucleic acid [DNA]-based typing) available.
- Available donor as defined in the protocol.
- Participant and/or legal guardian must sign informed consent.
- Adequate organ function defined by institutional transplant standards or defined as below:
- Cardiac: Left ventricular ejection fraction (LVEF) at rest > 40% with no clinical signs of cardiac failure. For participants aged < 13 years, shortening fraction (SF) = 26% by echocardiogram or multigated acquisition (MUGA) may be substituted for LVEF.
- Hepatic: Total bilirubin < 2.0 mg/dL unless Gilbert's disease is present
- Renal: For participants > 13.0 years of age at the time of enrollment: estimated creatinine clearance (CrCl) > 60 mL/minute (per institutional standard). For participants < 13.0 years of age at enrollment: glomerular filtration rate (GFR) estimated by the updated Schwartz formula = 90 mL/min/1.73 m2. If the estimated GFR is < 90 mL/min/1.73 m2, then renal function must be measured by 24-hour creatinine clearance or nuclear GFR, and must be > 50 mL/min/1.73 m2.
- Pulmonary: i. For participants > 13.0 years of age: Diffusing capacity of the lung for carbon monoxide (DLCO, corrected/adjusted for hemoglobin [Hb]) > 50%, or Spirometry with forced expiratory volume 1 (FEV1) > 50% predicted (without administration of bronchodilator) and forced vital capacity (FVC) > 50% predicted. ii. For participants < 13.0 years of age unable to perform pulmonary function tests (PFTs) due to age or developmental ability: (1) no evidence of dyspnea at rest and (2) no need for supplemental oxygen and (3) O2 saturation > 92% on room air at sea level (with lower levels allowed at higher elevations per established center standard of care [e.g., Utah, 4,200 feet above sea level, does not give supplemental oxygen unless below 90%]).
- Karnofsky or Lansky performance status = 60%.
- Females and males of childbearing potential must agree to practice 2 effective methods of contraception at the same time or agree to abstinence.
Treatment Sites in Georgia
1000 Johnson Ferry Road NE
Atlanta, GA 30342
404-851-8523
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts...
Click here to learn more about clinical trials.